The efficacy of prolonging treatment with peginterferon alfa-2b and ribavirin to 72 weeks in chronic hepatitis C genotype 1 patients HCV RNA positive at week 8 but negative at week 12

志保, 宮瀬; 賢一郎, 緒方; 克樹, 原岡; 祐子, 森下; 重俊, 藤山

doi:10.2957/kanzo.51.48

“…We also excluded 1 study on slow responders with HCV genotype 2/3 infection, 1 study that treated the slow responders by administration of triple therapy with histamine as a part of or throughout the subjects’ treatment duration [46], and 1 study with patients randomized at the baseline but not according to RVR and EVR [47]. Ultimately, 7 studies that met our criteria were included [48][49][50][51][52][53][54]. …”

Section: Resultsmentioning

confidence: 99%

Optimal Duration of Treatment for HCV Genotype 1 Infection in Slow Responders: A Meta-Analysis

Alavian¹,

Tabatabaei

²

,

Behnava

³

et al. 2011

View full text Add to dashboard Cite

BackgroundA head-to-head comparison of the 72-week and 48-week anti-HCV therapies in slow responders with genotype 1 infection has been performed in several randomized clinical trials (RCTs).ObjectivesThis review aimed at summarizing and pooling the results of these studies.Materials and MethodsRCTs that had evaluated the 72-week vs. 48-week anti-HCV therapy (peginterferon and ribavirin) in slow responders with HCV genotype 1 infection were systematically identified. A meta-analysis was performed using the random effects model. Heterogeneity in results was assessed on the basis of the Q statistics, and publication bias was evaluated by using Harbord’s modified test. The end point was set as a sustained virological response (SVR).ResultsData of 1206 subjects were retrieved from 7 studies. A total of 631 patients had received extended therapy. Slow virological responders who received the 72-week therapy had a significantly higher probability of achieving SVR than their counterpartswho received the 48-week therapy [RR = 1.44 (95% CI, 1.20–1.73)]. With regard to publication biases, the heterogeneity in funnel plots was not significant (P = 0.19, I2 = 30%, PHarbord = 0.1).ConclusionOur meta-analysis showed that the 72-week therapy with peginterferon and ibavirin is significantly superior to the standard 48-week therapy in slow responders th HCV genotype 1 infection.

show abstract

“…We also excluded 1 study on slow responders with HCV genotype 2/3 infection, 1 study that treated the slow responders by administration of triple therapy with histamine as a part of or throughout the subjects’ treatment duration [ 46 ], and 1 study with patients randomized at the baseline but not according to RVR and EVR [ 47 ]. Ultimately, 7 studies that met our criteria were included [ 48 ][ 49 ][ 50 ][ 51 ][ 52 ][ 53 ][ 54 ].…”

Section: Resultsmentioning

confidence: 99%

Optimal Duration of Treatment for HCV Genotype 1 Infection in Slow Responders: A Meta-Analysis

Alavian¹,

Tabatabaei

²

,

Behnava

³

et al. 2011

View full text Add to dashboard Cite

BackgroundA head-to-head comparison of the 72-week and 48-week anti-HCV therapies in slow responders with genotype 1 infection has been performed in several randomized clinical trials (RCTs).ObjectivesThis review aimed at summarizing and pooling the results of these studies.Materials and MethodsRCTs that had evaluated the 72-week vs. 48-week anti-HCV therapy (peginterferon and ribavirin) in slow responders with HCV genotype 1 infection were systematically identified. A meta-analysis was performed using the random effects model. Heterogeneity in results was assessed on the basis of the Q statistics, and publication bias was evaluated by using Harbord’s modified test. The end point was set as a sustained virological response (SVR).ResultsData of 1206 subjects were retrieved from 7 studies. A total of 631 patients had received extended therapy. Slow virological responders who received the 72-week therapy had a significantly higher probability of achieving SVR than their counterpartswho received the 48-week therapy [RR = 1.44 (95% CI, 1.20–1.73)]. With regard to publication biases, the heterogeneity in funnel plots was not significant (P = 0.19, I2 = 30%, PHarbord = 0.1).ConclusionOur meta-analysis showed that the 72-week therapy with peginterferon and ibavirin is significantly superior to the standard 48-week therapy in slow responders th HCV genotype 1 infection.

show abstract

Extended peginterferon plus ribavirin treatment for 72 weeks versus standard peginterferon plus ribavirin treatment for 48 weeks in chronic hepatitis C genotype 1 infected slow-responder adult patients

Katz¹,

Goldvaser

²

,

Gafter‐Gvili

³

et al. 2012

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

The efficacy of prolonging treatment with peginterferon alfa-2b and ribavirin to 72 weeks in chronic hepatitis C genotype 1 patients HCV RNA positive at week 8 but negative at week 12

Cited by 3 publications

References 4 publications

Optimal Duration of Treatment for HCV Genotype 1 Infection in Slow Responders: A Meta-Analysis

Optimal Duration of Treatment for HCV Genotype 1 Infection in Slow Responders: A Meta-Analysis

Optimal Duration of Treatment for HCV Genotype 1 Infection in Slow Responders: A Meta-Analysis

Extended peginterferon plus ribavirin treatment for 72 weeks versus standard peginterferon plus ribavirin treatment for 48 weeks in chronic hepatitis C genotype 1 infected slow-responder adult patients

Contact Info

Product

Resources

About